表紙
市場調査レポート

鼻咽頭炎(感冒):パイプライン分析

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229834
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
鼻咽頭炎(感冒):パイプライン分析 Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 45 Pages
概要

鼻咽頭炎には、発熱に伴う鼻炎・咽頭炎が発症するという特徴があります。また、幼児に非常によく見られる疾患です。ウイルスにより発症するため、治療や化学的予防の段階では、たいていは抗菌剤は必要ではありません。解熱剤(児童向けには非アスピリン性のもの)で高熱をおさえることができます。

当レポートでは、世界各国での鼻咽頭炎(感冒)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

鼻咽頭炎の概要

治療薬の開発

  • 鼻咽頭炎向けパイプライン製品:概要
  • 鼻咽頭炎向けパイプライン製品:比較分析

各企業で開発中の鼻咽頭炎治療薬

大学/研究機関で研究中の鼻咽頭炎治療薬

パイプライン製品の概略

  • 初期段階の製品
  • 不明確な段階にある製品

鼻咽頭炎治療薬:開発中の製品の一覧(企業別)

鼻咽頭炎治療薬:研究中の製品の一覧(大学/研究機関別)

鼻咽頭炎治療薬の開発に従事している企業

  • Charleston Laboratories, Inc.
  • Cocrystal Pharma, Inc.
  • Neos Therapeutics, Inc.
  • Orbis Biosciences, Inc.
  • Vernalis Plc

鼻咽頭炎:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (マレイン酸クロルフェニラミン + コデイン)
  • TRIM-21を標的とする消化器疾患/耳鼻咽頭疾患向け抗体
  • CCP-05
  • CCP-06
  • CCP-07
  • CCP-08
  • CLAT-313
  • グアイフェネシン ER
  • 咳/風邪向け小分子
  • 喘息/風邪向けのMAPK13抑制分子
  • 一般的な風邪向けのRNA依存性RNAポリメラーゼ抑制分子
  • ■鼻咽頭炎治療薬:最新の薬剤プロファイル

鼻咽頭炎治療薬:開発が休止状態の製品

鼻咽頭炎治療薬:開発が中止された製品

鼻咽頭炎関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8250IDB

Summary

Global Markets Direct's, 'Nasopharyngitis (Common Cold) - Pipeline Review, H2 2016', provides an overview of the Nasopharyngitis (Common Cold) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold)
  • The report reviews pipeline therapeutics for Nasopharyngitis (Common Cold) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Nasopharyngitis (Common Cold) therapeutics and enlists all their major and minor projects
  • The report assesses Nasopharyngitis (Common Cold) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Nasopharyngitis (Common Cold)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nasopharyngitis (Common Cold) Overview
  • Therapeutics Development
    • Pipeline Products for Nasopharyngitis (Common Cold) - Overview
    • Pipeline Products for Nasopharyngitis (Common Cold) - Comparative Analysis
  • Nasopharyngitis (Common Cold) - Therapeutics under Development by Companies
  • Nasopharyngitis (Common Cold) - Therapeutics under Investigation by Universities/Institutes
  • Nasopharyngitis (Common Cold) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Nasopharyngitis (Common Cold) - Products under Development by Companies
  • Nasopharyngitis (Common Cold) - Products under Investigation by Universities/Institutes
  • Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development
    • Charleston Laboratories, Inc.
    • Cocrystal Pharma, Inc.
    • Orbis Biosciences Inc
    • Vernalis Plc
  • Nasopharyngitis (Common Cold) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (levocetirizine dihydrochloride + montelukast sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-07 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCP-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLAT-313 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • guaifenesin ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit MAPK13 for Asthma and Cold - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nasopharyngitis (Common Cold) - Dormant Projects
  • Nasopharyngitis (Common Cold) - Discontinued Products
  • Nasopharyngitis (Common Cold) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
      • Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study
      • Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
      • Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
      • Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing
      • Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nasopharyngitis (Common Cold), H2 2016
  • Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories, Inc., H2 2016
  • Nasopharyngitis (Common Cold) - Pipeline by Cocrystal Pharma, Inc., H2 2016
  • Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences Inc, H2 2016
  • Nasopharyngitis (Common Cold) - Pipeline by Vernalis Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Nasopharyngitis (Common Cold) - Dormant Projects, H2 2016
  • Nasopharyngitis (Common Cold) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Nasopharyngitis (Common Cold), H2 2016
  • Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top